Google COVID19 monitor site
“FRANKFURT (Reuters) – The number of confirmed coronavirus cases in Germany has risen by 2,705 within a day to reach 16,662, the Robert Koch Institute for infectious diseases said on Saturday.
It said a total of 47 people had died after testing positive, an increase of 16 from a tally of 31 published on Friday.”
Hearing a great deal about Italy not so much about Germany on the news
Here’s a data point I found fascinating, but that will not show up for a while, if at all:
information like this, from NPR: Other countries can learn important lessons from Italy, says Dr. Giuseppe Remuzzi, co-author of a recent paper in The Lancet about the country’s dire situation. The takeaways include how to swiftly convert a general hospital into a coronavirus care unit with specially trained doctors and nurses. “We had dermatologists, eye doctors, pathologists, learning how to assist a person with a ventilator,” Remuzzi says. Some question why Italy was caught off guard when the virus outbreak was revealed on Feb. 21. Remuzzi says he is now hearing information about it from general practitioners. “They remember having seen very strange pneumonia, very severe, particularly in old people in December and even November,” he says. “This means that the virus was circulating, at least in [the northern region of] Lombardy and before we were aware of this outbreak occurring in China.” He says it was impossible to combat something you didn’t know existed.
It complements our still-unexplained ‘vaping deaths.’
From PubMed – NIH Medical research library
Cloroquine vs Hydroxy-chloroquine re: cytokine storm
J Antimicrob Chemother. 2020 Mar 20. pii: dkaa114. doi: 10.1093/jac/dkaa114. [Epub ahead of print]
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Zhou D1,2, Dai SM3, Tong Q3.
There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects.
We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
NB:Fair use – for non-profit, educational use
PubMed for more research exploratoin:
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status.
Guo YR1, Cao QD2, Hong ZS3, Tan YY1, Chen SD1, Jin HJ1, Tan KS4, Wang DY5, Yan Y6,7.
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention.
On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century.
As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO.
Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host.
The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe.
The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms.
The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm.
Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation.
In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.
PMID: 32169119 PMCID: PMC7068984 DOI: 10.1186/s40779-020-00240-0
[Indexed for MEDLINE] Free PMC Article
This is VERY TELLING…now the Janitor can write in your Cause of Death in Britain
Even if they die of something else will there be no consequences for Listing their Deaths as the Coronavirus TO INCREASE A PANIC narrative?
I went for a 1.5 hour “tour de machine”(that’s an old québécois expression for car ride) with my family today to break the monotony of self imposed quarantine. Then we made homemade bread which turned out too salty and shakshouka. I saw Raging Bull(1980) for the first time on cable, a great movie that I derived great enjoyment from. Hope everyone on SST had a good Sunday with their loved ones.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
113 total views
114 total views
115 total views